EUCTR2016-004586-67-GB进行中（未招募）1 期
BYLieve: A phase II, multicenter, open-label, three-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after prior treatments - BYLieve
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 340
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patient is male or female 18 years or older
- •- Patient is identified PIK3CA mutant status
- •- Patient has confirmed HER2-negative advanced breast cancer (aBC)
- •-Patient must be diagnosed with aBC with documented progression on or
- •after prior treatment
- •- Patient has histological and/or cytological confirmed ER+ and/or PgR+
- •- Patient has either measurable disease per RECIST v1.1 or at least one
- •predominantly lytic bone lesion must be present
- •- ECOG function of greater or equal to 2
- •- Patient has adequate bone marrow function
- •-Patient has adequate liver and renal function
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 280
排除标准
- •- patient has received prior treatment with any PI3K inhibitors
- •- patient with clinically manifest diabetes mellitus, or documented
- •steroid induced diabetes mellitus
- •-Patient has a concurrent malignancy or malignancy within 3 years of
- •study screening period, with the exception of adequately treated, basal
- •or squamous cell carcinoma, non-melanoma skin cancer or curatively
- •resected cervical cancer
- •-Patient has received radiotherapy = 4 weeks or limited field radiation
- •for palliation = 2 weeks prior to enrollment, and who has not recovered
- •to grade 1 or better from related side effects of such therapy
- •-History of acute pancreatitis within 1 year of screening or past medical
- •history of pancreatitis
- •-Bilateral diffuse lymphangitis carcinomatosis
- •-Patients with central nervous system (CNS) involvement unless they
- •meet ALL of the following criteria:
- •At least 4 weeks from prior therapy completion (including radiation
- •and/or surgery) to starting the study treatment
- •Clinically stable CNS tumor at the time of screening untreated or
- •without evidence of progressions for at least 4 weeks after treatment as
- •determined by clinical examination and brain imaging (MRI or CT) during
- •screening period and stable low dose of steroids for 2 weeks prior to
- •initiating study treatment
- •-Patient with severe liver impairment (Child Pugh score B/C)
- •-Patient has impairment of gastrointestinal (GI) function or GI disease
- •that may significantly alter the absorption of the study drugs
- •-Patient has documented pneumonitis which is active and requiring
- •-Patient has a history of severe cutaneous reactions like Stevens Johnson-Syndrome (SJS), Erythema Multiforme (EM), or Toxic Epidermal Necrolysis (TEN) or Drug Reaction with Eosinphilia and Systemic Symptoms (DRESS)
- •-Subjects with unresolved osteonecrosis of the jaw
研究者
相似试验
进行中（未招募）
1 期
Efficacy and safety of treatment with alpelisib plus endocrine therapy in patients with HR+, HER2- negative aBC, with PIK3CA mutations, whose disease has progressed on or after prior treatmentsHormone receptor positive, HER2-negative advanced breast cancerMedDRA version: 21.1Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-004586-67-DKovartis Pharma AG340
进行中（未招募）
1 期
Study assessing the efficacy and safety of alpelisib plus fulvestrant or letrozole, based on prior endocrine therapy, in patients with PIK3CA mutation with advanced breast cancer who have progressed on or after prior treatmentsHormone receptor positive, HER2-negative advanced breast cancerMedDRA version: 21.1Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 100000004864EUCTR2016-004586-67-BEovartis Pharma AG340
招募中
1 期
Study assessing the efficacy and safety of alpelisib plus fulvestrant or letrozole, based on prior endocrine therapy, in patients with PIK3CA mutation with advanced breast cancer who have progressed on or after prior treatmentsAdult patients with PIK3CA mutant, HR-positive, HER2-negative advanced breast cancerMedDRA version: 21.1Level: LLTClassification code: 10072737Term: Advanced breast cancer Class: 10029104CTIS2023-509167-24-00ovartis Pharma AG3
进行中（未招募）
1 期
Study assessing the efficacy and safety of alpelisib plus fulvestrant or letrozole, based on prior endocrine therapy, in patients with PIK3CA mutation with advanced breast cancer who have progressed on or after prior treatmentsHormone receptor positive, HER2-negative advanced breast cancerMedDRA version: 21.1Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 100000004864EUCTR2016-004586-67-NLovartis Pharma AG340
进行中（未招募）
1 期
Efficacy and safety of treatment with alpelisib plus endocrine therapy in patients with HR+, HER2- negative aBC, with PIK3CA mutations, whose disease has progressed on or after CDK 4/6 treatment with an aromatase inhibitor (AI) or fulvestrantHormone receptor positive, HER2-negative advanced breast cancerMedDRA version: 21.1Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 100000004864EUCTR2016-004586-67-ITOVARTIS PHARMA AG160